Grasso et al. retrospectively analyzed 101 patients with melanoma treated with Nivolumab alone or combined with Ipilimumab, showing that the antitumor T cell response and the corresponding downstream IFN-gamma signaling are the main drivers of clinical response or resistance to ICI therapy [38]. Here, IFNG is linked to melanoma.